XXXX suppresses thermal @entity1931 and mechanical @entity1931 in a @entity35 full thickness @entity130 pain model.

@entity1 @entity308 @entity1931 @entity4024 @entity14864 @entity35 @entity5 @entity19 @entity1022 @entity4524 @entity1372 @entity1576 @entity284 @entity158 @entity1286 @entity9 @entity3575 @entity734 @entity130
UNASSIGNED: @entity130 have been identified as the primary cause of injury in 5% of U.S. military personnel evacuated from Operations Iraqi Freedom and Enduring Freedom. Severe burn-associated @entity158 is typically treated with opioids such as @entity3575 , @entity1286 , and @entity284 . Side effects of opioids include @entity1576 , @entity308 , decrease in motor and cognitive function, as well as the development of @entity1931 , tolerance and @entity734 . These effects have led us to search for novel analgesics for the treatment of burn-associated @entity158 in wounded combat service members. @entity1022 ( @entity4524 ) is a selective voltage-gated @entity1372 channel blocker currently in clinical trials as an analgesic. A phase 3 clinical trial for @entity5 -related @entity158 has been completed and phase 3 clinical trials on chemotherapy-induced @entity9 are planned. It has also been shown in @entity19 to inhibit the development of chemotherapy-induced @entity9 . @entity4524 was originally identified as a neurotoxin in marine animals but has now been shown to be safe in @entity1 at therapeutic doses. The antinociceptive effects of @entity4524 are thought to be due to inhibition of @entity4024 ion influx required for initiation and conduction of nociceptive impulses. One @entity4524 sensitive @entity1372 channel, @entity14864 , has been shown to be essential in lowering the @entity158 threshold after @entity130 . To date, the analgesic effect of @entity4524 has not been tested in burn-associated @entity158 . Male @entity35 were subjected to a full thickness @entity130 on the right hind paw. @entity4524 (8 g/kg) was administered once a day systemically by subcutaneous injection beginning 3 days post @entity130 and continued through 7 days post @entity130 . Thermal @entity1931 and mechanical @entity1931 were assessed 60 and 120min post injection on each day of @entity4524 treatment. @entity4524 significantly reduced thermal @entity1931 at all days tested and had a less robust, but statistically significant suppressive effect on mechanical @entity1931 . These results suggest that systemic @entity4524 may be an effective, rapidly acting analgesic for battlefield @entity130 and has the potential for replacing or reducing the need for opioid analgesics.
